Page last updated: 2024-11-02

palmidrol and Allodynia

palmidrol has been researched along with Allodynia in 34 studies

palmidrol: a cannabinoid receptor-inactive eCB-related molecule used as prophylactic in helping to prevent respiratory viral infection
palmitoyl ethanolamide : An N-(long-chain-acyl)ethanolamine that is the ethanolamide of palmitic (hexadecanoic) acid.

Research Excerpts

ExcerptRelevanceReference
", PEA co-ultramicronized with the natural antioxidant quercetin (PEA-Q), administered orally in two different rat models of inflammatory and OA pain, namely carrageenan paw oedema and sodium monoiodoacetate (MIA)-induced OA."7.85A novel composite formulation of palmitoylethanolamide and quercetin decreases inflammation and relieves pain in inflammatory and osteoarthritic pain models. ( Britti, D; Crupi, R; Cuzzocrea, S; Di Paola, R; Evangelista, M; Fusco, R; Gugliandolo, E; Impellizzeri, D; Morittu, VM; Schievano, C, 2017)
" The antiinflammatory activity of synthetic cannabinoid nabilone in the rat model of carrageenan-induced acute hindpaw inflammation was compared with that of the endocannabinoid palmitoylethanolamide and the nonsteroidal antiinflammatory drug indomethacin."7.71Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. ( Colleoni, M; Conti, S; Costa, B; Giagnoni, G; Parolaro, D, 2002)
" (1) The therapeutic effects of the cannabinoid anandamide and the putative CB2 agonist palmitoylethanolamide were tested in a model of persistent visceral pain (turpentine inflammation of the urinary bladder)."7.70The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. ( Hasnie, FS; Jaggar, SI; Rice, AS; Sellaturay, S, 1998)
", PEA co-ultramicronized with the natural antioxidant quercetin (PEA-Q), administered orally in two different rat models of inflammatory and OA pain, namely carrageenan paw oedema and sodium monoiodoacetate (MIA)-induced OA."3.85A novel composite formulation of palmitoylethanolamide and quercetin decreases inflammation and relieves pain in inflammatory and osteoarthritic pain models. ( Britti, D; Crupi, R; Cuzzocrea, S; Di Paola, R; Evangelista, M; Fusco, R; Gugliandolo, E; Impellizzeri, D; Morittu, VM; Schievano, C, 2017)
" Intraplantar injection of CAR led to a time-dependent development of peripheral inflammation, in terms of paw edema, cytokine release in paw exudates, nitrotyrosine formation, inducible nitric oxide synthase and cyclooxygenase-2 expression."3.83A new co-micronized composite containing palmitoylethanolamide and polydatin shows superior oral efficacy compared to their association in a rat paw model of carrageenan-induced inflammation. ( Bruschetta, G; Cordaro, M; Crupi, R; Cuzzocrea, S; Esposito, E; Gugliandolo, E; Impellizzeri, D; Siracusa, R, 2016)
"The analgesic and anti-hyperalgesic effects of cannabinoid- and vanilloid-like compounds, plus the fatty acid amide hydrolase (FAAH) inhibitor Cyclohexylcarbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597), and acetaminophen, were evaluated in the phenyl-p-quinone (PPQ) pain model, using different routes of administration in combination with opioid and cannabinoid receptor antagonists."3.73Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice. ( Cichewicz, DL; Haller, VL; Welch, SP, 2006)
" The antiinflammatory activity of synthetic cannabinoid nabilone in the rat model of carrageenan-induced acute hindpaw inflammation was compared with that of the endocannabinoid palmitoylethanolamide and the nonsteroidal antiinflammatory drug indomethacin."3.71Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. ( Colleoni, M; Conti, S; Costa, B; Giagnoni, G; Parolaro, D, 2002)
" (1) The therapeutic effects of the cannabinoid anandamide and the putative CB2 agonist palmitoylethanolamide were tested in a model of persistent visceral pain (turpentine inflammation of the urinary bladder)."3.70The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. ( Hasnie, FS; Jaggar, SI; Rice, AS; Sellaturay, S, 1998)
"Obesity is associated with augmented peripheral inflammation and pain sensitivity in response to inflammatory stimulation, but the underlying mechanisms remain unclear."1.40Down-regulation of PPARα in the spinal cord contributes to augmented peripheral inflammation and inflammatory hyperalgesia in diet-induced obese rats. ( Fu, Z; Li, D; Liang, L; Wang, J; Zhang, Q; Zhao, L, 2014)
" The lipidic nature and large particle size of PEA in the native state may limit its solubility and bioavailability when given orally, however."1.40Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain. ( Bruschetta, G; Cordaro, M; Crupi, R; Cuzzocrea, S; Esposito, E; Impellizzeri, D; Siracusa, R, 2014)
"Spinal AEA reduces neuropathic pain by acting at both cannabinoid CB1 receptors and transient receptor potential vanilloid-1 (TRPV1) channels."1.39Full inhibition of spinal FAAH leads to TRPV1-mediated analgesic effects in neuropathic rats and possible lipoxygenase-mediated remodeling of anandamide metabolism. ( Cristino, L; De Petrocellis, L; Di Marzo, V; Korostynski, M; Makuch, W; Malek, N; Petrosino, S; Przewlocka, B; Slezak, M; Starowicz, K; Zychowska, M, 2013)
"To induce hyperalgesia, rat paws were treated with intraplantar prostaglandin E2 (PGE2, 2μg)."1.39Probable involvement of Ca(2+)-activated Cl(-) channels (CaCCs) in the activation of CB1 cannabinoid receptors. ( Duarte, ID; Pacheco, Dda F; Romero, TR, 2013)
" In addition, the dosage of nitrite in the homogenized paw, as determined by colorimetric assay, indicated that exogenous PEA is able to induce NO release."1.38Involvement of the L-arginine/nitric oxide/cyclic guanosine monophosphate pathway in peripheral antinociception induced by N-palmitoyl-ethanolamine in rats. ( Cortes, SF; Duarte, ID; Galdino, GS; Perez, AC; Resende, LC; Romero, TR; Silva, GC, 2012)
"Inflammatory hyperalgesia was measured following intraplantar injection of carrageenan."1.35Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain. ( Alexander, SP; Barrett, DA; Bennett, AJ; Chapman, V; Garle, MJ; Jhaveri, MD; Kendall, DA; Patel, A; Richardson, D; Robinson, I; Sagar, DR; Sun, Y, 2008)
"Anandamide (AEA) is an endogenous cannabinoid ligand acting predominantly on the cannabinoid 1 (CB(1)) receptor, but it is also an agonist on the capsaicin VR(1)/TRPV(1) receptor."1.32Inhibitory effect of anandamide on resiniferatoxin-induced sensory neuropeptide release in vivo and neuropathic hyperalgesia in the rat. ( Bölcskei, K; Helyes, Z; Németh, J; Pintér, E; Szolcsányi, J; Thán, M, 2003)
"Referred hyperalgesia to a somatopically appropriate superficial site is a cardinal symptom of visceral inflammatory pain and has been demonstrated after turpentine-induced urinary bladder inflammation in the rat."1.31Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder. ( Farquhar-Smith, WP; Rice, AS, 2001)

Research

Studies (34)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (5.88)18.2507
2000's8 (23.53)29.6817
2010's21 (61.76)24.3611
2020's3 (8.82)2.80

Authors

AuthorsStudies
Lang-Illievich, K1
Klivinyi, C1
Rumpold-Seitlinger, G1
Dorn, C1
Bornemann-Cimenti, H1
Siracusa, R4
Fusco, R4
Cordaro, M4
Peritore, AF2
D'Amico, R2
Gugliandolo, E4
Crupi, R6
Genovese, T1
Evangelista, M3
Di Paola, R4
Cuzzocrea, S9
Impellizzeri, D7
Ardizzone, A1
Casili, G1
Lanza, M1
Esposito, E5
Britti, D1
Schievano, C1
Morittu, VM1
Bartolucci, ML1
Marini, I1
Bortolotti, F1
Bruschetta, G3
Portelli, M1
Militi, A1
Oteri, G1
Di Cesare Mannelli, L1
D'Agostino, G3
Pacini, A1
Russo, R4
Zanardelli, M1
Ghelardini, C1
Calignano, A4
Starowicz, K1
Makuch, W1
Korostynski, M1
Malek, N1
Slezak, M1
Zychowska, M1
Petrosino, S1
De Petrocellis, L1
Cristino, L1
Przewlocka, B1
Di Marzo, V1
Wang, J1
Zhang, Q1
Zhao, L1
Li, D1
Fu, Z1
Liang, L1
Khasabova, IA1
Yao, X1
Paz, J1
Lewandowski, CT1
Lindberg, AE1
Coicou, L1
Burlakova, N1
Simone, DA1
Seybold, VS1
Donvito, G2
Bettoni, I2
Comelli, F2
Colombo, A1
Costa, B3
Iuvone, T3
Affaitati, G1
De Filippis, D3
Lopopolo, M1
Grassia, G1
Lapenna, D1
Negro, L2
Costantini, R1
Vaia, M2
Cipollone, F1
Ialenti, A1
Giamberardino, MA1
Tronino, D1
Offerta, A1
Ostacolo, C1
De Caro, C1
Puglia, C1
Blasi, P1
Wilkerson, JL1
Damaj, MI1
Lichtman, AH1
Jhaveri, MD1
Richardson, D1
Robinson, I1
Garle, MJ1
Patel, A1
Sun, Y1
Sagar, DR1
Bennett, AJ1
Alexander, SP1
Kendall, DA1
Barrett, DA1
Chapman, V1
Colleoni, M2
Giagnoni, G2
La Rana, G2
Sasso, O3
Iacono, A2
Mattace Raso, G1
Loverme, J1
Piomelli, D2
Meli, R2
Luongo, L1
Cipriano, M1
Palazzo, E1
Cinelli, MP2
de Novellis, V1
Maione, S1
Vitiello, S1
Raso, GM1
Vallée, M1
Piazza, PV1
Romero, TR3
Duarte, ID3
Galdino, GS1
Silva, GC1
Resende, LC1
Perez, AC1
Cortes, SF1
Pacheco, Dda F1
Moreno-Sanz, G1
Martucci, C1
Realini, N1
Dionisi, M1
Mengatto, L1
Duranti, A1
Tarozzo, G1
Tarzia, G1
Mor, M1
Bertorelli, R1
Reggiani, A1
Taylor, BK1
Helyes, Z1
Németh, J1
Thán, M1
Bölcskei, K1
Pintér, E1
Szolcsányi, J1
Haller, VL1
Cichewicz, DL1
Welch, SP1
Mazzari, S1
Canella, R1
Petrelli, L1
Marcolongo, G1
Leon, A1
Jaggar, SI2
Hasnie, FS1
Sellaturay, S1
Rice, AS3
Farquhar-Smith, WP2
Conti, S1
Parolaro, D1

Reviews

1 review available for palmidrol and Allodynia

ArticleYear
New insights in mast cell modulation by palmitoylethanolamide.
    CNS & neurological disorders drug targets, 2013, Feb-01, Volume: 12, Issue:1

    Topics: Amides; Animals; Clinical Trials as Topic; Endocannabinoids; Ethanolamines; Humans; Hyperalgesia; In

2013

Trials

1 trial available for palmidrol and Allodynia

ArticleYear
The Effect of Palmitoylethanolamide on Pain Intensity, Central and Peripheral Sensitization, and Pain Modulation in Healthy Volunteers-A Randomized, Double-Blinded, Placebo-Controlled Crossover Trial.
    Nutrients, 2022, Oct-01, Volume: 14, Issue:19

    Topics: Amides; Analgesics; Anti-Inflammatory Agents; Cross-Over Studies; Double-Blind Method; Ethanolamines

2022

Other Studies

32 other studies available for palmidrol and Allodynia

ArticleYear
The Protective Effects of Pre- and Post-Administration of Micronized Palmitoylethanolamide Formulation on Postoperative Pain in Rats.
    International journal of molecular sciences, 2020, Oct-18, Volume: 21, Issue:20

    Topics: Amides; Animals; Brain-Derived Neurotrophic Factor; Calcium-Binding Proteins; Ethanolamines; Extrace

2020
Effect of Ultra-Micronized-Palmitoylethanolamide and Acetyl-l-Carnitine on Experimental Model of Inflammatory Pain.
    International journal of molecular sciences, 2021, Feb-17, Volume: 22, Issue:4

    Topics: Acetylcarnitine; Amides; Animals; Carrageenan; Cell Count; Cyclooxygenase 2; Disease Models, Animal;

2021
A novel composite formulation of palmitoylethanolamide and quercetin decreases inflammation and relieves pain in inflammatory and osteoarthritic pain models.
    BMC veterinary research, 2017, Aug-02, Volume: 13, Issue:1

    Topics: Administration, Oral; Amides; Animals; Anti-Inflammatory Agents; Carrageenan; Drug Combinations; Ede

2017
Micronized palmitoylethanolamide reduces joint pain and glial cell activation.
    Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2018, Volume: 67, Issue:10

    Topics: Amides; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Edema; Ethanolamin

2018
The neuroprotective effects of micronized PEA (PEA-m) formulation on diabetic peripheral neuropathy in mice.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2019, Volume: 33, Issue:10

    Topics: Amides; Analgesics; Animals; Anti-Inflammatory Agents; Apoptosis; Cytokines; Diabetic Neuropathies;

2019
Palmitoylethanolamide is a disease-modifying agent in peripheral neuropathy: pain relief and neuroprotection share a PPAR-alpha-mediated mechanism.
    Mediators of inflammation, 2013, Volume: 2013

    Topics: Amides; Animals; Blotting, Western; Endocannabinoids; Ethanolamines; Hyperalgesia; Immunohistochemis

2013
Full inhibition of spinal FAAH leads to TRPV1-mediated analgesic effects in neuropathic rats and possible lipoxygenase-mediated remodeling of anandamide metabolism.
    PloS one, 2013, Volume: 8, Issue:4

    Topics: Amides; Amidohydrolases; Analgesia; Animals; Arachidonate 15-Lipoxygenase; Arachidonic Acids; Benzam

2013
Down-regulation of PPARα in the spinal cord contributes to augmented peripheral inflammation and inflammatory hyperalgesia in diet-induced obese rats.
    Neuroscience, 2014, Oct-10, Volume: 278

    Topics: Amides; Animals; Diet, High-Fat; Down-Regulation; Ethanolamines; Hyperalgesia; Inflammation; Male; M

2014
Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain.
    Journal of neuroinflammation, 2014, Aug-28, Volume: 11

    Topics: Administration, Oral; Amides; Analgesics; Animals; Carrageenan; Chemistry, Pharmaceutical; Chromatog

2014
JZL184 is anti-hyperalgesic in a murine model of cisplatin-induced peripheral neuropathy.
    Pharmacological research, 2014, Volume: 90

    Topics: Amides; Analgesics; Animals; Antineoplastic Agents; Arachidonic Acids; Benzodioxoles; Cells, Culture

2014
Palmitoylethanolamide relieves pain and preserves pancreatic islet cells in a murine model of diabetes.
    CNS & neurological disorders drug targets, 2015, Volume: 14, Issue:4

    Topics: Amides; Analgesics; Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Ethanolamines;

2015
Ultramicronized palmitoylethanolamide reduces viscerovisceral hyperalgesia in a rat model of endometriosis plus ureteral calculosis: role of mast cells.
    Pain, 2016, Volume: 157, Issue:1

    Topics: Amides; Animals; Chymases; Disease Models, Animal; Endometriosis; Ethanolamines; Female; Hyperalgesi

2016
Nanoparticles prolong N-palmitoylethanolamide anti-inflammatory and analgesic effects in vivo.
    Colloids and surfaces. B, Biointerfaces, 2016, May-01, Volume: 141

    Topics: Adult; Amides; Analgesics; Animals; Anti-Inflammatory Agents; Calorimetry, Differential Scanning; Ca

2016
A new co-micronized composite containing palmitoylethanolamide and polydatin shows superior oral efficacy compared to their association in a rat paw model of carrageenan-induced inflammation.
    European journal of pharmacology, 2016, 07-05, Volume: 782

    Topics: Active Transport, Cell Nucleus; Administration, Oral; Amides; Animals; Carrageenan; Cell Line, Tumor

2016
Palmitoylethanolamide Reverses Paclitaxel-Induced Allodynia in Mice.
    The Journal of pharmacology and experimental therapeutics, 2016, Volume: 359, Issue:2

    Topics: Amides; Amines; Animals; Cyclohexanecarboxylic Acids; Drug Synergism; Ethanolamines; Gabapentin; gam

2016
Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain.
    Neuropharmacology, 2008, Volume: 55, Issue:1

    Topics: Amides; Amidohydrolases; Animals; Benzamides; Cannabinoid Receptor Modulators; Carbamates; Carrageen

2008
The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors.
    Pain, 2008, Oct-31, Volume: 139, Issue:3

    Topics: Amides; Analgesics, Non-Narcotic; Animals; Cytoplasmic Granules; Drug Evaluation, Preclinical; Endoc

2008
Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-kappaB nuclear signalling in dorsal root ganglia.
    European journal of pharmacology, 2009, Jun-24, Volume: 613, Issue:1-3

    Topics: Amides; Analgesics; Animals; Butyrates; Carrageenan; Cell Nucleus; Central Nervous System; Cyclooxyg

2009
Palmitoylethanolamide reduces granuloma-induced hyperalgesia by modulation of mast cell activation in rats.
    Molecular pain, 2011, Jan-10, Volume: 7

    Topics: Amides; Animals; Carrageenan; Endocannabinoids; Ethanolamines; Ganglia, Spinal; Granuloma; Hyperalge

2011
Implication of allopregnanolone in the antinociceptive effect of N-palmitoylethanolamide in acute or persistent pain.
    Pain, 2012, Volume: 153, Issue:1

    Topics: Amides; Analgesics; Animals; Endocannabinoids; Ethanolamines; Hyperalgesia; Male; Mice; Pain; Pain M

2012
N-palmitoyl-ethanolamine (PEA) induces peripheral antinociceptive effect by ATP-sensitive K+-channel activation.
    Journal of pharmacological sciences, 2012, Volume: 118, Issue:2

    Topics: Amides; Analgesics; Animals; Dequalinium; Dinoprostone; Disease Models, Animal; Dose-Response Relati

2012
Involvement of the L-arginine/nitric oxide/cyclic guanosine monophosphate pathway in peripheral antinociception induced by N-palmitoyl-ethanolamine in rats.
    Journal of neuroscience research, 2012, Volume: 90, Issue:7

    Topics: Amides; Analgesics; Animals; Arginine; Cyclic GMP; Disease Models, Animal; Endocannabinoids; Ethanol

2012
Probable involvement of Ca(2+)-activated Cl(-) channels (CaCCs) in the activation of CB1 cannabinoid receptors.
    Life sciences, 2013, May-02, Volume: 92, Issue:14-16

    Topics: Amides; Analysis of Variance; Animals; Arachidonic Acids; Calcium Channel Blockers; Cannabinoid Rece

2013
Antinociceptive effects of the N-acylethanolamine acid amidase inhibitor ARN077 in rodent pain models.
    Pain, 2013, Volume: 154, Issue:3

    Topics: Amides; Amidohydrolases; Analgesics; Animals; Burns; Carbamates; Carrageenan; Dose-Response Relation

2013
N-acylethanolamine acid amidase (NAAA), a new path to unleash PPAR-mediated analgesia.
    Pain, 2013, Volume: 154, Issue:3

    Topics: Amides; Amidohydrolases; Analgesics; Animals; Carbamates; Endocannabinoids; Enzyme Inhibitors; Ethan

2013
Inhibitory effect of anandamide on resiniferatoxin-induced sensory neuropeptide release in vivo and neuropathic hyperalgesia in the rat.
    Life sciences, 2003, Sep-19, Volume: 73, Issue:18

    Topics: Amides; Animals; Arachidonic Acids; Calcitonin Gene-Related Peptide; Camphanes; Cannabinoids; Diterp

2003
Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice.
    European journal of pharmacology, 2006, Sep-28, Volume: 546, Issue:1-3

    Topics: Acetaminophen; Amides; Analgesics; Animals; Arachidonic Acids; Benzamides; Benzoquinones; Camphanes;

2006
N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation.
    European journal of pharmacology, 1996, Apr-11, Volume: 300, Issue:3

    Topics: Amides; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Cell De

1996
The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain.
    Pain, 1998, Volume: 76, Issue:1-2

    Topics: Amides; Analgesics; Animals; Arachidonic Acids; Cannabinoids; Capillary Permeability; Cystitis; Elec

1998
Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder.
    Anesthesiology, 2001, Volume: 94, Issue:3

    Topics: Adjuvants, Immunologic; Amides; Analgesics; Animals; Arachidonic Acids; Area Under Curve; Cannabinoi

2001
Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat.
    British journal of pharmacology, 2002, Volume: 135, Issue:1

    Topics: Acute Disease; Amides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Camphanes; Cannabinoid Rece

2002
Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB(1) and CB(2)-like receptors.
    Pain, 2002, Volume: 97, Issue:1-2

    Topics: Amides; Animals; Arachidonic Acids; Camphanes; Cannabinoid Receptor Modulators; Cannabinoids; Endoca

2002